Mouse Anti-TGFBR1 Recombinant Antibody (VS3-CJ919) (CAT#: VS3-CJ919)

• Immunogen
• KLH-conjugated synthetic peptide encompassing a sequence within human ALK5

• Host Species
• Mouse

• Type
• Mouse IgG2a

• Specificity
• Human TGFBR1

• Species Reactivity
• Human

• Applications
• IHC

• Conjugate
• Unconjugated

• Purification
• Immunogen affinity chromatography

• Purity
• >95% as determined by SDS-PAGE

• Format
• Liquid

• Buffer
• 50% Glycerol, 0.2% BSA, PBS.

• Preservative
• 0.01% Sodium Azide

• Storage
• Store at 4°C for short term. Aliquot and store at -20°C for long term. Avoid repeated freeze/thaw cycles.

• Shipping
• Shipped at 4°C

• Application Notes
• This antibody has been tested for use in Immunohistochemistry (1:100-1:300).

• Alternative Names
• AAT5; ALK5; ESS1; LDS1; MSSE; SKR4; TBRI; ALK-5; LDS1A; LDS2A; TBR-i; TGFR-1; ACVRLK4; tbetaR-I

• Gene ID
• 7046

• UniProt ID
• P36897

• Sequence Similarities
• Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.

• Cellular Localization
• Cell junction, Cell membrane, Membrane, Tight junction

• Post Translation Modifications
• Phosphorylated at basal levels in the absence of ligand. Activated upon phosphorylation by TGFBR2, mainly in the GS domain. Phosphorylation in the GS domain abrogates FKBP1A-binding.
  N-Glycosylated.
  Ubiquitinated; undergoes ubiquitination catalyzed by several E3 ubiquitin ligases including SMURF1, SMURF2 and NEDD4L2. Results in the proteasomal and/or lysosomal degradation of the receptor thereby negatively regulating its activity. Deubiquitinated by USP15, leading to stabilization of the protein and enhanced TGF-beta signal. Its ubiquitination and proteasome-mediated degradation is negatively regulated by SDCBP (PubMed:25893292).

• Protein Refseq
• NP_001124388.1; NP_001293139.1; NP_004603.1

• Function
• Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.

Secondary Antibody

• 2RD-A1464-YJ
• Goat Anti-Mouse IgG2a Secondary antibody

• 2RD-A1564-YJ
• Rabbit Anti-Mouse IgG2a Secondary antibody (Clone RM219)

Recommended Dilution Buffer

• MRO-0253YJ
• Reconstitution Buffer PBS